# Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

> **NCT06259669** · — · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 958 (estimated)

## Conditions studied

- Pregnancy Related
- Atopic Dermatitis

## Interventions

- **DRUG:** Ruxolitinib Cream

## Key facts

- **NCT ID:** NCT06259669
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-13
- **Primary completion:** 2032-08-01
- **Final completion:** 2033-08-01
- **Target enrollment:** 958 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06259669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06259669, "Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06259669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*